China's drug regulator, the National Medical Products Administration (NMPA), has approved several GLP-1-based obesity drugs ahead of equivalent U.S. decisions, giving an early look at how different mechanisms perform. Two of the more notable approvals are ecnoglutide, from Hangzhou Sciwind Biosciences, and mazdutide, developed by Innovent Biologics under license from Eli Lilly. Neither drug is FDA-approved, and neither is available in the United States. Here's how they differ.

Different Mechanisms

Ecnoglutide is a single-target GLP-1 receptor agonist, but with an engineering twist: it's described as "cAMP-biased," meaning it's designed to preferentially activate the cAMP signaling pathway downstream of the GLP-1 receptor while minimizing recruitment of a protein called β-arrestin, compared with conventional GLP-1 drugs. The stated rationale is that this bias might improve the drug's effect-to-side-effect ratio, though how much that distinction matters clinically, versus simply being a long-acting GLP-1 agonist like several others, is still being evaluated independently of the company's own framing. It's designed as a long-acting injectable.

Mazdutide takes a different approach: it's a dual agonist that activates both the GLP-1 receptor and the glucagon (GCG) receptor. Glucagon receptor activation is thought to increase energy expenditure, which is a different mechanism than appetite suppression alone, and mazdutide's developers have marketed it as the world's first approved dual GCG/GLP-1 drug. This dual-agonist strategy is the same broad concept behind drugs like survodutide and pemvidutide, covered elsewhere on this site, though each molecule differs in its specific receptor-activation balance.

Regulatory Status and Timeline

Mazdutide was approved by the NMPA on June 27, 2025, for chronic weight management in Chinese adults with overweight or obesity who also have at least one weight-related comorbidity, such as elevated blood sugar or blood pressure. Innovent holds the Chinese marketing rights under a 2019 licensing deal with Eli Lilly, which retains development rights outside China; Lilly has a Phase 2 trial of the same molecule underway at U.S. sites, but mazdutide is not approved anywhere outside China as of this writing. Ecnoglutide received NMPA approval for chronic weight management in adults with overweight or obesity in early 2026. Both drugs are also approved or in development for type 2 diabetes indications in China, consistent with how most of this drug class first established itself in diabetes before expanding to obesity.

How the Trial Data Compare

In mazdutide's Phase 3 GLORY-1 trial (more than 600 Chinese adults, 48 weeks), the higher of two tested doses produced an average 14.8% weight loss from baseline, versus 0.5% on placebo; about half of patients on that dose lost at least 15% of their body weight, versus about 2% on placebo. The trial also reported substantial reductions in liver fat among patients who started with elevated levels, consistent with glucagon-receptor activation's effects on the liver.

Ecnoglutide's supporting data, from the trial program behind its weight-management approval, showed an average 15.1% weight loss after subtracting the placebo response, with roughly 93% of patients reaching a threshold the company characterized as clinically meaningful weight loss. The two figures — mazdutide's 14.8% and ecnoglutide's 15.1% — are close enough that drawing a confident "winner" from cross-trial comparisons isn't appropriate; the trials differed in design, population, and duration, and neither drug has been tested head-to-head against the other in the same study.

What This Means Going Forward

Both drugs illustrate a broader pattern: China's faster or differently structured approval pathway has let several GLP-1-class obesity drugs reach patients there before equivalent U.S. decisions, giving researchers and competitors an early, real-world data source even while FDA review of comparable molecules continues. Neither ecnoglutide nor mazdutide should be read as interchangeable with each other or with FDA-approved U.S. options like semaglutide or tirzepatide; mechanism, regulatory status, and the populations studied all differ. Anyone interested in either drug's U.S. availability should watch for FDA filings specifically, rather than treating a China-only approval as predictive of U.S. timing.